SEC Form 4Coverage since May 21, 2026
$AMLX insider trading
Over the last 12 months, Amylyx Pharmaceuticals insiders reported 1 buy totaling $51K and 1 sale totaling $539K across SEC Form 4 filings. 50% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $51K 1 event
- Sold · 12m
- $539K 1 event
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 50% pre-arranged plans
Side
Price · $AMLX · 12Mvia TradingView
Top insiders · 12m
Firestone Karen—1× · $51K
Mazzariello GinaChief Legal Officer1× · $539K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Mazzariello GinaChief Legal Officer · O | ▼ Sale | 30,000 | $17.96 | $539K | -14.3% | plan · 2 tranches |
| May 21, 2026 | Firestone KarenD | ▲ Buy | 3,800 | $13.51 | $51K | +6% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AMLX feed.